ABSTRACT
Objective: To compare the healing effects of dried and acellular human amniotic membrane and Mepitel for coverage of split-thickness graft donor site [STGDS]
Methods: Twenty patients who underwent STGDS regeneration surgery in identical anatomic regions were enrolled in this randomized controlled clinical trial conducted in Hazrate Fatemeh hospital [Iran]. Patients were randomly assigned in 3 groups of wound dressing; group A by Mepitel, group B AmiCare [Dried amniotic membrane] and group C OcuReg-A [Acellular amniotic membrane]. Re-epithelization rate [healing time], pain sensation, scar formation and infection rate were assessed till complete healing was achieved
Results: Our results showed no significant difference between Amicare, OcuReg-A and Mepitel in the features analyzed by us including: Re-epithelization rate [healing time] p=0.573, Pain sensation p=day 4[th]: 0.131, day 8[th]: 0.93 and day 12[th]: 0.365, Scar formation p>0.05 and Infection rate
Conclusion: Our findings confirmed the safety and efficacy of Ami Care [dried amniotic membrane] and OcuReg-A [Acellular amniotic membrane] in treatment of split-thickness donor site in comparison with Mepitel as a standard wound dressing. Trial registration number: IRCT201511118177N12